Investing in INCY? Read Our Focused Overview.

Shares of Incyte have moved 0.5% today, and are now trading at a price of $59.82. In contrast, the S&P 500 index saw a -0.0% change. Today's trading volume is 244,817 compared to the stock's average volume of 1,647,965.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. Based in Wilmington, United States the company has 2,324 full time employees and a market cap of $13,404,944,384.

The company is now trading -27.98% away from its average analyst target price of $83.06 per share. The 16 analysts following the stock have set target prices ranging from $65.0 to $114.0, and on average give Incyte a rating of buy.

Over the last 12 months INCY shares have declined by -12.0%, which represents a difference of -28.0% when compared to the S&P 500. The stock's 52 week high is $86.29 per share and its 52 week low is $58.54. Based on Incyte's average net margin growth of 7.0% over the last 6 years, its core business remains strong and the stock price may recover in the long term.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2023-02-07 3,394,635 340,660 10 -68.75
2022-02-08 2,986,267 948,581 32 390.91
2021-02-09 2,666,702 -295,697 -11 -152.38
2020-02-13 2,158,759 446,906 21 250.0
2019-02-14 1,881,883 109,493 6 130.0
2018-02-15 1,536,216 -313,142 -20
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.